Home › Multiple Myeloma › New York › Albany
Multiple Myeloma clinical trials in Albany, NY
4 studies for Multiple Myeloma are looking for participants at sites in and around Albany (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
- Research Site, Albany
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- New York Oncology Hematology, Albany
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
RecruitingPhase 3
- New York Oncology Hematology, Albany
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecruitingPhase 3
- Research Site, Albany
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
Other studies in Albany
- Non-Small Cell Lung Cancer9 studies
- Cardiovascular Disease7 studies
- Obesity6 studies
- Heart Failure6 studies
- Cancer (all types)5 studies
- Burkitt Lymphoma4 studies
- High Blood Pressure4 studies
- Bladder Cancer4 studies
- Metastatic Cancer4 studies
- Prostate Cancer4 studies
- Digestive Diseases4 studies
- Breast Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.